Rosetta Genomics (ROSG) Announces Distribution Agreement with Teva (TEVA)

January 8, 2009 8:40 AM EST

Rosetta Genomics, Ltd. (NASDQ: ROSG) has signed an exclusive distribution agreement with Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA). Under the terms of the agreement Teva will offer Rosetta Genomics' miRview(TM) tests in Israel and Turkey. The terms of the deal were not disclosed.

Using microRNAs, a group of recently discovered non-coding genes found to be highly sensitive biomarkers, Rosetta Genomics has developed proprietary technologies which can be the basis for a wide range of diagnostic tests.

The following tests will be distributed by Teva Pharmaceuticals:

miRview(TM) mets - This test can accurately identify the primary tumor site in patients presenting with metastatic cancer, as well in patients whose tumor has not been identified, and consequently been labeled Cancer of Unknown Primary (CUP).

miRview(TM) squamous - Using a single microRNA, miRview(TM) squamous differentiates squamous from non-squamous, non-small cell lung cancer (NSCLC) patients.

miRview(TM) meso - The test leverages microRNA's high specificity as biomarkers, to differentiate mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung.

Rosetta Genomics is a developer of microRNA-based molecular diagnostics. [SM]

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?